Who Owns BioCryst Pharmaceuticals Stock?
NASDAQ: BCRXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 95.03%
- Held by insiders
- 1.27%
- Institutional holders
- 426
- Institutions 95.0%
- Insiders 1.3%
- Public and other 3.7%
Who owns BioCryst Pharmaceuticals stock?
Institutional investors own about 95.0% of BioCryst Pharmaceuticals's shares, spread across 426 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 1.27% of BCRX.
The largest institutional holders are Blackrock Inc. (9.46%), Deerfield Management Company, L.P (6.02%) and State Street Corporation (4.78%). Together, the top 10 institutions control 46.6% of shares outstanding. In their latest filings, 5 of the top 10 institutions increased their BCRX positions and 4 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of BCRX
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Blackrock Inc. | 24.33M | 9.46% | +1.9% |
| Deerfield Management Company, L.P | 15.49M | 6.02% | +2.6% |
| State Street Corporation | 12.29M | 4.78% | -19.1% |
| Vanguard Capital Management LLC | 11.27M | 4.38% | -0.9% |
| TCG Crossover Management, LLC | 11.02M | 4.28% | 0.0% |
| Vanguard Portfolio Management LLC | 10.53M | 4.09% | -5.4% |
| Perceptive Advisors Llc | 10.30M | 4.00% | -0.1% |
| Janus Henderson Group Ltd. | 10.26M | 3.99% | +15.2% |
| Two Sigma Investments, LP | 7.20M | 2.80% | +6.3% |
| Jones Hill Capital LP | 7.08M | 2.75% | +100.0% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of BCRX
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 8.07M | 3.14% |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 6.89M | 2.68% |
| iShares Trust-iShares Russell 2000 ETF | 5.79M | 2.25% |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.91M | 1.13% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 2.84M | 1.10% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 2.54M | 0.99% |
| abrdn Healthcare Investors | 2.32M | 0.90% |
| VANGUARD HORIZON FUNDS-Vanguard Strategic Equity Fund | 2.26M | 0.88% |
| iShares Trust-iShares Russell 2000 Growth ETF | 2.10M | 0.82% |
| abrdn Healthcare Opportunities Fund | 2.09M | 0.81% |
Frequently asked questions
Who is the largest shareholder of BioCryst Pharmaceuticals?
Blackrock Inc. is the largest institutional shareholder of BCRX, owning 9.46% of shares outstanding (24.33M shares) as of its latest 13F filing.
What percentage of BioCryst Pharmaceuticals is owned by institutions?
Institutions own about 95.0% of BCRX shares and 96.3% of the public float.
How much of BioCryst Pharmaceuticals do insiders own?
Insiders, such as officers and directors, own about 1.27% of BCRX shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.